Viral Genetics Section, U.S. Military HIV Research Program, Walter Reed Army Institute of Research
National Institutes of Health, National Institute of General Medical Sciences
People: Joshua Herbeck, Steven Goodreau, Morgane Rolland
2017 – 2021 Continue Reading Modeling the Evolutionary and Public Health Impacts of HIV Adaptation in Response to Vaccination
King HAD, Subra C, Tourtellott E, Swafford I, Basu S, Rossman M, Phillips L, Obarorakpor N, Ding S, Ferrari MG, Beck Z, Lewitus E, Bai H, Dong M, Slike BM, Kim D, Dussupt V, Mendez-Rivera L, Eisel N, Zhang L, Williams LD, Tomaras GD, Finzi A, Matyas GR, Krebs SJ, Rolland M, Rao M, Paquin-Proulx D, Bolton DL. (2026). Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates. Journal of virology
Mullins JI, Deng W, Giorgi EE, Magaret CA, Rolland M, Bhattacharya T, Westfall DH, Yssel AEJ, Bumgarner RE, Murrell B, Ndung'u T, Robb ML, Rossenkhan R, Edlefsen PT, Dong KL, Chen L, Gwashu-Nyangiwe A, Zhao H, Thebus R, Ndabambi N, Galvao B, Sawe F, Nitayaphan S, York T, Matten D, Murrell H, Pankow AP, Juraska M, Ludwig J, Hural J, Cohen MS, Corey L, McElrath MJ, Gilbert PB, Williamson C. (2026). Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection. Nature communications, 17(1)
Williamson C, Moodley C, Magaret CA, Giorgi EE, Rolland M, Westfall DH, Yssel A, Deng W, Rossenkhan R, Mkhize NN, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, York T, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Cohen P, Lambson B, Kaldine H, Bhebhe S, Juraska M, Bai H, deCamp AC, Miner MD, Ludwig J, Molitor C, Beaume N, Matten D, Huang Y, Zhang L, Reeves DB, Mayer B, Karuna ST, Hural JA, Morris L, Montefiori D, Bumgarner RE, Moore PL, Edlefsen PT, Edupuganti S, Mgodi N, McElrath MJ, Cohen MS, Corey L, Gilbert PB, Mullins JI. (2026). Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials. Nature communications
King HAD, Brammer D, Lewitus E, Fennessey CM, Manalang KM, Shrader HR, Andrew S, Kuri P, Lind M, Pham P, Sanders-Buell E, Bai H, Mason R, Song K, McCarthy E, Helmold Hait S, Todd JP, Pegu A, Foulds KE, Lifson JD, Keele BF, Rolland M, Roederer M, Bolton DL. (2025). SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants. Proceedings of the National Academy of Sciences of the United States of America, 122(5)
Williamson C, Curry L, Mkhize NN, Giorgi EE, Magaret CA, Lambson BE, Hons SB, Kaldine H, Moyo-Gwete T, Rolland M, Rossenkhan R, Garcia NMG, Moodley C, Yssel A, Huang Y, Marsden AA, Reeves DB, Mayer BT, Bumgarner RE, Beaume N, Westfall DH, Juraska M, deCamp AC, Murrell H, Bai H, Deng W, Pankow AP, Bhattacharya T, York T, Ndabambi N, Chen L, Zhao H, Gwashu-Nyangiri A, Thebus R, Cohen P, Murrell B, Karuna S, Hural J, Mgodi N, Edupuganti S, Morris L, Montefiori D, McElrath MJ, Cohen MS, Corey L, Edlefsen PT, Gilbert PB, Moore PL, Mullins JI. (2025). VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials. bioRxiv : the preprint server for biology
Avelino-Silva VI, Stone M, Di Germanio C, Lanteri MC, Bakkour S, Grebe E, Custer B, Deng X, Pillai S, Buccheri R, Kleinman SH, Vasan S, Rolland M, Phanuphak N, Sacdalan C, Akapirat S, de Souza M, Kallas EG, Mateos SdOG, Sabino EC, Busch MP, Norris PJ, . (2025). HIV serologic reactivity varies with time of ART initiation in persons on long-term ART. Journal of clinical microbiology
Rossenkhan R, Giorgi EE, Shao D, Ludwig J, Labuschagne P, Magaret CA, Ndung'u T, Muema D, Gounder K, Dong KL, Walker BD, Rolland M, Robb ML, Eller LA, Sawe F, Nitayaphan S, Grebe E, Busch MP, Delaney KP, Facente S, Carpp LN, deCamp AC, Huang Y, Korber B, Juraska M, Rudnicki E, Kosmider E, Reeves DB, Mayer BT, Hural J, Deng W, Westfall DH, Yssel A, Matten D, Bhattacharya T, Corey L, Gilbert PB, Williamson C, Mullins JI, Edlefsen PT. (2025). Bayesian estimation of HIV acquisition dates for prevention trials. mBio
Mdluli T, Wollen-Roberts S, Merbah M, Beckman B, Li Y, Alrubayyi A, Curtis DJ, Shubin Z, Barrera MD, Boeckelman J, Duncan S, Thapa P, Kim D, Costanzo MC, Bai H, Dearlove BL, Hooper JW, Kwilas SA, Paquin-Proulx D, Eller MA, Eller LA, Kibuuka H, Mwesigwa B, Kosgei J, Sawe F, Oyieko J, Ntinginya N, Mwakisisile J, Jani I, Viegas E, Iroezindu M, Akintunde A, Paolino K, Robb ML, Ward L, McLean C, Luhn K, Robinson C, Ake JA, Rolland M. (2025). Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses. Science translational medicine, 17(792)
Li Y, Dearlove BL, Lewitus E, Bai H, Shangguan S, Pham P, Bose M, Sanders-Buell E, Miller SH, Rosario Y, Ehrenberg PK, Tovanabutra S, Thomas R, Ake JA, Vasan S, Eller LA, Nitayaphan S, Maganga L, Kibuuka H, Sawe FK, Robb ML, Rolland M. (2025). High peak viraemia followed by spontaneous HIV-1 control in women living with HIV-1 subtype A1 in East Africa. Journal of the International AIDS Society, 28(8)
Ulrichs T, Rolland M, Wu J, Nunes MC, El Guerche-Séblain C, Chit A. (2024). Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies. Expert review of vaccines
Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI. (2024). Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proceedings of the National Academy of Sciences of the United States of America, 121(4)
Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, Bryant C, McGuire S, Kennedy J, Chen WH, Hajduczki A, Mdluli T, Valencia-Ruiz A, Amare MF, Matyas GR, Rao M, Rolland M, Mascola JR, De Rosa SC, McElrath MJ, Montefiori DC, Serebryannyy L, McDermott AB, Peel SA, Collins ND, Joyce MG, Robb ML, Michael NL, Vasan S, Modjarrad K, . (2024). SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. The Lancet. Microbe
Lewitus E, Li Y, Rolland M. (2024). HIV-1 Vif global diversity and possible APOBEC-mediated response since 1980. Virus evolution, 11(1)
Magaret CA, Li L, deCamp AC, Rolland M, Juraska M, Williamson BD, Ludwig J, Molitor C, Benkeser D, Luedtke A, Simpkins B, Heng F, Sun Y, Carpp LN, Bai H, Dearlove BL, Giorgi EE, Jongeneelen M, Brandenburg B, McCallum M, Bowen JE, Veesler D, Sadoff J, Gray GE, Roels S, Vandebosch A, Stieh DJ, Le Gars M, Vingerhoets J, Grinsztejn B, Goepfert PA, de Sousa LP, Silva MST, Casapia M, Losso MH, Little SJ, Gaur A, Bekker LG, Garrett N, Truyers C, Van Dromme I, Swann E, Marovich MA, Follmann D, Neuzil KM, Corey L, Greninger AL, Roychoudhury P, Hyrien O, Gilbert PB. (2024). Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Nature communications, 15(1)
Bai H, Lewitus E, Li Y, Thomas PV, Zemil M, Merbah M, Peterson CE, Thuraisamy T, Rees PA, Hajduczki A, Dussupt V, Slike B, Mendez-Rivera L, Schmid A, Kavusak E, Rao M, Smith G, Frey J, Sims A, Wieczorek L, Polonis V, Krebs SJ, Ake JA, Vasan S, Bolton DL, Joyce MG, Townsley S, Rolland M. (2024). Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding. Nature communications, 15(1)
Lewitus E, Li Y, Bai H, Pham P, Rolland M. (2024). HIV-1 Gag, Pol, and Env diversified with limited adaptation since the 1980s. mBio
Mdluli T, Slike BM, Curtis DJ, Shubin Z, Tran U, Li Y, Dussupt V, Mendez-Rivera L, Pinyakorn S, Stieh DJ, Tomaka FL, Schuitemaker H, Pau MG, Colby DJ, Kroon E, Sacdalan C, de Souza M, Phanupak N, Hsu DC, Ananworanich J, Ake JA, Trautmann L, Vasan S, Robb ML, Krebs SJ, Paquin-Proulx D, Rolland M. (2024). Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption. Cell reports, 43(6)
Sankhala RS, Lal KG, Jensen JL, Dussupt V, Mendez-Rivera L, Bai H, Wieczorek L, Mayer SV, Zemil M, Wagner DA, Townsley SM, Hajduczki A, Chang WC, Chen WH, Donofrio GC, Jian N, King HAD, Lorang CG, Martinez EJ, Rees PA, Peterson CE, Schmidt F, Hart TJ, Duso DK, Kummer LW, Casey SP, Williams JK, Kannan S, Slike BM, Smith L, Swafford I, Thomas PV, Tran U, Currier JR, Bolton DL, Davidson E, Doranz BJ, Hatziioannou T, Bieniasz PD, Paquin-Proulx D, Reiley WW, Rolland M, Sullivan NJ, Vasan S, Collins ND, Modjarrad K, Gromowski GD, Polonis VR, Michael NL, Krebs SJ, Joyce MG. (2024). Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques. Nature communications, 15(1)
Dearlove BL, Fries AC, Epsi NJ, Richard SA, Ganesan A, Huprikar N, Lindholm DA, Mende K, Colombo RE, Colombo C, Bai H, Larson DT, Ewers EC, Lalani T, Smith AG, Berjohn CM, Maves RC, Jones MU, Saunders D, Maldonado CJ, Mody RM, Bazan SE, Tribble DR, Burgess T, Simons MP, Agan BK, Pollett SD, Rolland M. (2024). SARS-CoV-2 variant replacement constrains vaccine-specific viral diversification. Virus evolution, 10(1)
Westfall DH, Deng W, Pankow A, Murrell H, Chen L, Zhao H, Williamson C, Rolland M, Murrell B, Mullins JI. (2024). Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations-Application to HIV-1 quasispecies. Virus evolution, 10(1)
Westfall DH, Deng W, Pankow A, Murrell H, Chen L, Zhao H, Williamson C, Rolland M, Murrell B, Mullins JI. (2023). Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations - application to HIV-1 quasispecies. bioRxiv : the preprint server for biology
Lewitus E, Bai H, Rolland M. (2023). Design of a pan-betacoronavirus vaccine candidate through a phylogenetically informed approach. Science advances, 9(3)
Sankhala RS, Dussupt V, Chen WH, Bai H, Martinez EJ, Jensen JL, Rees PA, Hajduczki A, Chang WC, Choe M, Yan L, Sterling SL, Swafford I, Kuklis C, Soman S, King J, Corbitt C, Zemil M, Peterson CE, Mendez-Rivera L, Townsley SM, Donofrio GC, Lal KG, Tran U, Green EC, Smith C, de Val N, Laing ED, Broder CC, Currier JR, Gromowski GD, Wieczorek L, Rolland M, Paquin-Proulx D, van Dyk D, Britton Z, Rajan S, Loo YM, McTamney PM, Esser MT, Polonis VR, Michael NL, Krebs SJ, Modjarrad K, Joyce MG. (2023). Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain. Structure (London, England : 1993)
Takata H, Mitchell JL, Pacheco J, Pagliuzza A, Pinyakorn S, Buranapraditkun S, Sacdalan C, Leyre L, Nathanson S, Kakazu JC, Intasan J, Prueksakaew P, Chomchey N, Phanuphak N, de Souza M, Haddad EK, Rolland M, Tovanabutra S, Vasan S, Hsu DC, Chomont N, Trautmann L, , . (2023). An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8(+) T cell magnitude and short-lived differentiation status. Cell host & microbe, 31(9)
Sankhala RS, Dussupt V, Donofrio G, Gromowski GD, De La Barrera RA, Larocca RA, Mendez-Rivera L, Lee A, Choe M, Zaky W, Mantus G, Jensen JL, Chen WH, Gohain N, Bai H, McCracken MK, Mason RD, Leggat D, Slike BM, Tran U, Jian N, Abbink P, Peterson R, Mendes EA, Freitas de Oliveira Franca R, Calvet GA, Bispo de Filippis AM, McDermott A, Roederer M, Hernandez M, Albertus A, Davidson E, Doranz BJ, Rolland M, Robb ML, Lynch RM, Barouch DH, Jarman RG, Thomas SJ, Modjarrad K, Michael NL, Krebs SJ, Joyce MG. (2023). Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes. Cell reports, 42(8)
Wieczorek L, Sanders-Buell E, Zemil M, Lewitus E, Kavusak E, Heller J, Molnar S, Rao M, Smith G, Bose M, Nguyen A, Dhungana A, Okada K, Parisi K, Silas D, Slike B, Ganesan A, Okulicz J, Lalani T, Agan BK, Crowell TA, Darden J, Rolland M, Vasan S, Ake J, Krebs SJ, Peel S, Tovanabutra S, Polonis VR. (2023). Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States. PLoS pathogens, 19(12)
Jensen JL, Sankhala RS, Dussupt V, Bai H, Hajduczki A, Lal KG, Chang WC, Martinez EJ, Peterson CE, Golub ES, Rees PA, Mendez-Rivera L, Zemil M, Kavusak E, Mayer SV, Wieczorek L, Kannan S, Doranz BJ, Davidson E, Yang ES, Zhang Y, Chen M, Choe M, Wang L, Gromowski GD, Koup RA, Michael NL, Polonis VR, Rolland M, Modjarrad K, Krebs SJ, Joyce MG. (2023). Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity. Journal of virology, 97(7)
Chen WH, Hajduczki A, Martinez EJ, Bai H, Matz H, Hill TM, Lewitus E, Chang WC, Dawit L, Peterson CE, Rees PA, Ajayi AB, Golub ES, Swafford I, Dussupt V, David S, Mayer SV, Soman S, Kuklis C, Corbitt C, King J, Choe M, Sankhala RS, Thomas PV, Zemil M, Wieczorek L, Hart T, Duso D, Kummer L, Yan L, Sterling SL, Laing ED, Broder CC, Williams JK, Davidson E, Doranz BJ, Krebs SJ, Polonis VR, Paquin-Proulx D, Rolland M, Reiley WW, Gromowski GD, Modjarrad K, Dooley H, Joyce MG. (2023). Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity. Nature communications, 14(1)
Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Curtis DJ, Currier JR, Mendez-Rivera L, Dussupt V, Krebs SJ, De La Barrera R, Michael NL, Paquin-Proulx D, Eller MA, Koren MA, Modjarrad K, Rolland M. (2023). Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine. EBioMedicine, (97)
Lewitus E, Hoang J, Li Y, Bai H, Rolland M. (2022). Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens. PLoS computational biology, 18(10)
Wieczorek L, Zemil M, Merbah M, Dussupt V, Kavusak E, Molnar S, Heller J, Beckman B, Wollen-Roberts S, Peachman KK, Darden JM, Krebs S, Rolland M, Peel SA, Polonis VR. (2022). Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. Frontiers in immunology, (13)
DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, Bloom JD, Bloyet LM, Bonenfant G, Boon ACM, Boritz EA, Bratt DL, Bricker TL, Brown L, Buchser WJ, Carreño JM, Cohen-Lavi L, Darling TL, Davis-Gardner ME, Dearlove BL, Di H, Dittmann M, Doria-Rose NA, Douek DC, Drosten C, Edara VV, Ellebedy A, Fabrizio TP, Ferrari G, Florence WC, Fouchier RAM, Franks J, García-Sastre A, Godzik A, Gonzalez-Reiche AS, Gordon A, Haagmans BL, Halfmann PJ, Ho DD, Holbrook MR, Huang Y, James SL, Jaroszewski L, Jeevan T, Johnson RM, Jones TC, Joshi A, Kawaoka Y, Kercher L, Koopmans MPG, Korber B, Koren E, Koup RA, LeGresley EB, Lemieux JE, Liebeskind MJ, Liu Z, Livingston B, Logue JP, Luo Y, McDermott AB, McElrath MJ, Meliopoulos VA, Menachery VD, Montefiori DC, Mühlemann B, Munster VJ, Munt JE, Nair MS, Netzl A, Niewiadomska AM, O'Dell S, Pekosz A, Perlman S, Pontelli MC, Rockx B, Rolland M, Rothlauf PW, Sacharen S, Scheuermann RH, Schmidt SD, Schotsaert M, Schultz-Cherry S, Seder RA, Sedova M, Sette A, Shabman RS, Shen X, Shi PY, Shukla M, Simon V, Stumpf S, Sullivan NJ, Thackray LB, Theiler J, Thomas PG, Trifkovic S, Türeli S, Turner SA, Vakaki MA, van Bakel H, VanBlargan LA, Vincent LR, Wallace ZS, Wang L, Wang M, Wang P, Wang W, Weaver SC, Webby RJ, Weiss CD, Wentworth DE, Weston SM, Whelan SPJ, Whitener BM, Wilks SH, Xie X, Ying B, Yoon H, Zhou B, Hertz T, Smith DJ, Diamond MS, Post DJ, Suthar MS. (2022). Defining the risk of SARS-CoV-2 variants on immune protection. Nature
Mdluli T, Li Y, Pinyakorn S, Reeves DB, Cardozo-Ojeda EF, Yates A, Intasan J, Tipsuk S, Phanuphak N, Sacdalan C, Colby DJ, Kroon E, Crowell TA, Thomas R, Robb ML, Ananworanich J, de Souza M, Phanuphak P, Stieh DJ, Tomaka FL, Trautmann L, Ake JA, Hsu DC, Francisco LV, Vasan S, Rolland M. (2022). Acute HIV-1 infection viremia associate with rebound upon treatment interruption. Med (New York, N.Y.)
Lewitus E, Townsley SM, Li Y, Donofrio GC, Dearlove BL, Bai H, Sanders-Buell E, O'Sullivan AM, Bose M, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Eller LA, Michael NL, Polonis VR, Ake JA, Vasan S, Robb ML, Tovanabutra S, Krebs SJ, Rolland M. (2022). HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS pathogens, 18(3)
Takata H, Kakazu JC, Mitchell JL, Kroon E, Colby DJ, Sacdalan C, Bai H, Ehrenberg PK, Geretz A, Buranapraditkun S, Pinyakorn S, Intasan J, Tipsuk S, Suttichom D, Prueksakaew P, Chalermchai T, Chomchey N, Phanuphak N, de Souza M, Michael NL, Robb ML, Haddad EK, Crowell TA, Vasan S, Valcour VG, Douek DC, Thomas R, Rolland M, Chomont N, Ananworanich J, Trautmann L, . (2022). Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8(+) T cells. EBioMedicine, (84)
Swan DA, Rolland M, Herbeck JT, Schiffer JT, Reeves DB. (2022). Evolution during primary HIV infection does not require adaptive immune selection. Proceedings of the National Academy of Sciences of the United States of America, 119(7)
Lewitus E, Rolland M. (2022). Does HIV-1 virulence matter in the ART era?. Med (New York, N.Y.), 3(4)
Dearlove B, Tovanabutra S, Owen CL, Lewitus E, Li Y, Sanders-Buell E, Bose M, O'Sullivan AM, Kijak G, Miller S, Poltavee K, Lee J, Bonar L, Harbolick E, Ahani B, Pham P, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Kim JH, Eller LA, Vasan S, Gramzinski R, Michael NL, Robb ML, Rolland M, . (2021). Factors influencing estimates of HIV-1 infection timing using BEAST. PLoS computational biology, 17(2)
Rolland M, Gilbert PB. (2021). Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. PLoS pathogens, 17(3)
Dussupt V, Sankhala RS, Mendez-Rivera L, Townsley SM, Schmidt F, Wieczorek L, Lal KG, Donofrio GC, Tran U, Jackson ND, Zaky WI, Zemil M, Tritsch SR, Chen WH, Martinez EJ, Ahmed A, Choe M, Chang WC, Hajduczki A, Jian N, Peterson CE, Rees PA, Rutkowska M, Slike BM, Selverian CN, Swafford I, Teng IT, Thomas PV, Zhou T, Smith CJ, Currier JR, Kwong PD, Rolland M, Davidson E, Doranz BJ, Mores CN, Hatziioannou T, Reiley WW, Bieniasz PD, Paquin-Proulx D, Gromowski GD, Polonis VR, Michael NL, Modjarrad K, Joyce MG, Krebs SJ. (2021). Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature immunology
Townsley SM, Donofrio GC, Jian N, Leggat DJ, Dussupt V, Mendez-Rivera L, Eller LA, Cofer L, Choe M, Ehrenberg PK, Geretz A, Gift S, Grande R, Lee A, Peterson C, Piechowiak MB, Slike BM, Tran U, Joyce MG, Georgiev IS, Rolland M, Thomas R, Tovanabutra S, Doria-Rose NA, Polonis VR, Mascola JR, McDermott AB, Michael NL, Robb ML, Krebs SJ. (2021). B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. Cell host & microbe
Li Y, Bai H, Sanders-Buell E, Dussupt V, Townsley S, Donofrio G, Bose M, O'Sullivan AM, Kibuuka H, Maganga L, Nitayaphan S, Kosgei J, Pitisuttithum P, Rerks-Ngarm S, Eller LA, Michael NL, Robb ML, Ake J, Vasan S, Tovanabutra S, Krebs SJ, Rolland M. (2021). Limited evidence for a relationship between HIV-1 glycan shield features in early infection and the development of neutralization breadth. Journal of virology
Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. (2021). SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell reports, 37(12)
Shangguan S, Ehrenberg PK, Geretz A, Yum L, Kundu G, May K, Fourati S, Nganou-Makamdop K, Williams LD, Sawant S, Lewitus E, Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Rerks-Ngarm S, Rolland M, Douek DC, Gilbert P, Tomaras GD, Michael NL, Vasan S, Thomas R. (2021). Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. eLife, (10)
Mitchell JL, Pollara J, Dietze K, Edwards RW, Nohara J, N'guessan KF, Zemil M, Buranapraditkun S, Takata H, Li Y, Muir R, Kroon E, Pinyakorn S, Jha S, Manasnayakorn S, Chottanapund S, Thantiworasit P, Prueksakaew P, Ratnaratorn N, Nuntapinit B, Fox L, Tovanabutra S, Paquin-Proulx D, Wieczorek L, Polonis VR, Maldarelli F, Haddad EK, Phanuphak P, Sacdalan CP, Rolland M, Phanuphak N, Ananworanich J, Vasan S, Ferrari G, Trautmann L. (2021). Anti-HIV antibody development up to one year after antiretroviral therapy initiation in acute HIV infection. The Journal of clinical investigation
Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M. (2021). RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus evolution, 7(2)
Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. (2021). SARS-CoV-2 Variants in Patients with Immunosuppression. The New England journal of medicine, 385(6)
Reeves DB, Rolland M, Dearlove BL, Li Y, Robb ML, Schiffer JT, Gilbert P, Cardozo-Ojeda EF, Mayer BT. (2021). Timing HIV infection with a simple and accurate population viral dynamics model. Journal of the Royal Society, Interface, 18(179)
Dussupt V, Sankhala RS, Gromowski GD, Donofrio G, De La Barrera RA, Larocca RA, Zaky W, Mendez-Rivera L, Choe M, Davidson E, McCracken MK, Brien JD, Abbink P, Bai H, Bryan AL, Bias CH, Berry IM, Botero N, Cook T, Doria-Rose NA, Escuer AGI, Frimpong JA, Geretz A, Hernandez M, Hollidge BS, Jian N, Kabra K, Leggat DJ, Liu J, Pinto AK, Rutvisuttinunt W, Setliff I, Tran U, Townsley S, Doranz BJ, Rolland M, McDermott AB, Georgiev IS, Thomas R, Robb ML, Eckels KH, Barranco E, Koren M, Smith DR, Jarman RG, George SL, Stephenson KE, Barouch DH, Modjarrad K, Michael NL, Joyce MG, Krebs SJ. (2020). Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nature medicine, 26(2)
Rolland M, Tovanabutra S, Dearlove B, Li Y, Owen CL, Lewitus E, Sanders-Buell E, Bose M, O'Sullivan A, Rossenkhan R, Labuschagne JPL, Edlefsen PT, Reeves DB, Kijak G, Miller S, Poltavee K, Lee J, Bonar L, Harbolick E, Ahani B, Pham P, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Eller LA, Gramzinski R, Kim JH, Michael NL, Robb ML,. (2020). Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. PLoS pathogens, 16(2)
Reeves DB, Huang Y, Duke ER, Mayer BT, Cardozo-Ojeda EF, Boshier FA, Swan DA, Rolland M, Robb ML, Mascola JR, Cohen MS, Corey L, Gilbert PB, Schiffer JT. (2020). Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS computational biology, 16(2)
Dearlove B, Lewitus E, Bai H, Li Y, Reeves DB, Joyce MG, Scott PT, Amare MF, Vasan S, Michael NL, Modjarrad K, Rolland M. (2020). A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proceedings of the National Academy of Sciences of the United States of America
Cale EM, Bai H, Bose M, Messina MA, Colby DJ, Sanders-Buell E, Dearlove B, Li Y, Engeman E, Silas D, O'Sullivan AM, Mann B, Pinyakorn S, Intasan J, Benjapornpong K, Sacdalan C, Kroon E, Phanuphak N, Gramzinski R, Vasan S, Robb ML, Michael NL, Lynch RM, Bailer RT, Pagliuzza A, Chomont N, Pegu A, Doria-Rose NA, Trautmann L, Crowell TA, Mascola JR, Ananworanich J, Tovanabutra S, Rolland M, . (2020). Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. The Journal of clinical investigation, 130(6)
Joyce MG, Sankhala RS, Chen WH, Choe M, Bai H, Hajduczki A, Yan L, Sterling SL, Peterson CE, Green EC, Smith C, de Val N, Amare M, Scott P, Laing ED, Broder CC, Rolland M, Michael NL, Modjarrad K. (2020). A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein. bioRxiv : the preprint server for biology
Mdluli T, Jian N, Slike B, Paquin-Proulx D, Donofrio G, Alrubayyi A, Gift S, Grande R, Bryson M, Lee A, Dussupt V, Mendez-Riveria L, Sanders-Buell E, Chenine AL, Tran U, Li Y, Brown E, Edlefsen PT, O'Connell R, Gilbert P, Nitayaphan S, Pitisuttihum P, Rerks-Ngarm S, Robb ML, Gramzinski R, Alter G, Tovanabutra S, Georgiev IS, Ackerman ME, Polonis VR, Vasan S, Michael NL, Kim JH, Eller MA, Krebs SJ, Rolland M. (2020). RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS pathogens, 16(12)
Merbah M, Wollen-Roberts S, Shubin Z, Li Y, Bai H, Dussupt V, Mendez-Rivera L, Slike B, Krebs SJ, Modjarrad K, Michael NL, Rolland M. (2020). A high-throughput multiplex assay to characterize flavivirus-specific immunoglobulins. Journal of immunological methods, (487)
Om K, Paquin-Proulx D, Montero M, Peachman K, Shen X, Wieczorek L, Beck Z, Weiner JA, Kim D, Li Y, Mdluli T, Shubin Z, Bryant C, Sharma V, Tokarev A, Dawson P, White Y, Appelbe O, Klatt NR, Tovanabutra S, Estes JD, Matyas GR, Ferrari G, Alving CR, Tomaras GD, Ackerman ME, Michael NL, Robb ML, Polonis V, Rolland M, Eller MA, Rao M, Bolton DL. (2020). Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS pathogens, 16(9)
Bai H, Li Y, Michael NL, Robb ML, Rolland M. (2019). The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes. PLoS computational biology, 15(6)
Lewitus E, Rolland M. (2019). A non-parametric analytic framework for within-host viral phylogenies and a test for HIV-1 founder multiplicity. Virus evolution, 5(2)
Rolland M. (2019). HIV-1 phylogenetics and vaccines. Current opinion in HIV and AIDS, 14(3)
Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J, . (2019). Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. The lancet. HIV, 6(5)
Rolland M. (2019). Editorial: HIV-1 transmission and phylogenetics. Current opinion in HIV and AIDS, 14(3)
Rossenkhan R, Rolland M, Labuschagne JPL, Ferreira RC, Magaret CA, Carpp LN, Matsen Iv FA, Huang Y, Rudnicki EE, Zhang Y, Ndabambi N, Logan M, Holzman T, Abrahams MR, Anthony C, Tovanabutra S, Warth C, Botha G, Matten D, Nitayaphan S, Kibuuka H, Sawe FK, Chopera D, Eller LA, Travers S, Robb ML, Williamson C, Gilbert PB, Edlefsen PT. (2019). Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 11(7)
Karch CP, Bai H, Torres OB, Tucker CA, Michael NL, Matyas GR, Rolland M, Burkhard P, Beck Z. (2019). Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. Nanomedicine : nanotechnology, biology, and medicine, (16)
Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J, . (2018). Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nature medicine, 24(7)
Kijak GH, Sanders-Buell E, Chenine AL, Eller MA, Goonetilleke N, Thomas R, Leviyang S, Harbolick EA, Bose M, Pham P, Oropeza C, Poltavee K, O'Sullivan AM, Billings E, Merbah M, Costanzo MC, Warren JA, Slike B, Li H, Peachman KK, Fischer W, Gao F, Cicala C, Arthos J, Eller LA, O'Connell RJ, Sinei S, Maganga L, Kibuuka H, Nitayaphan S, Rao M, Marovich MA, Krebs SJ, Rolland M, Korber BT, Shaw GM, Michael NL, Robb ML, Tovanabutra S, Kim JH. (2017). Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS pathogens, 13(7)
deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB. (2017). Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PloS one, 12(11)
Herbeck JT, Peebles K, Edlefsen PT, Rolland M, Murphy JT, Gottlieb GS, Abernethy N, Mullins JI, Mittler JE, Goodreau SM. (2018). HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine. Vaccine, 36(4)
Robb ML, Eller LA, Rolland M. (2016). Acute HIV-1 Infection in Adults in East Africa and Thailand. The New England journal of medicine, 375(12)
Rolland M. (2016). HIV-1 immune evasion-a threat to effective vaccines?. Nature medicine, 22(6)
Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M. (2015). HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nature medicine, 21(10)
Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Kijak GH, Bose M, , Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB. (2015). Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS computational biology, 11(2)
Rolland M, Modjarrad K. (2015). Multiple co-circulating HIV-1 subtypes in the Middle East and North Africa. AIDS (London, England), 29(11)
Dommaraju K, Kijak G, Carlson JM, Larsen BB, Tovanabutra S, Geraghty DE, Deng W, Maust BS, Edlefsen PT, Sanders-Buell E, Ratto-Kim S, deSouza MS, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Mullins JI, Kim JH, Rolland M. (2014). CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. PLoS One, 9(10)
Edlefsen PT, Gilbert PB, Rolland M. (2013). Sieve analysis in HIV-1 vaccine efficacy trials. Current opinion in HIV and AIDS, 8(5)
Rolland M, Manocheewa S, Swain JV, Lanxon-Cookson EC, Kim M, Westfall DH, Larsen BB, Gilbert PB, Mullins JI. (2013). HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity. Journal of virology, 87(10)
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH. (2012). Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature, 490(7420)
Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI. (2011). Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature medicine, 17(3)
Rolland M, Frahm N, Nickle DC, Jojic N, Deng W, Allen TM, Brander C, Heckerman DE, Mullins JI. (2011). Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences. PLoS One, 6(3)
Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, Zhao H, Wong K, Stoddard JN, Raugi D, Sorensen S, Genowati I, Birditt B, McKay A, Diem K, Maust BS, Deng W, Collier AC, Stekler JD, McElrath MJ, Mullins JI. (2011). Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. Journal of virology, 85(15)
Rolland M, Gilbert P. (2012). Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS research and human retroviruses, 28(4)
Rolland M, Carlson JM, Manocheewa S, Swain JV, Lanxon-Cookson E, Deng W, Rousseau CM, Raugi DN, Learn GH, Maust BS, Coovadia H, Ndung'u T, Goulder PJ, Walker BD, Brander C, Heckerman DE, Mullins JI. (2010). Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated selection pressure and compensatory dynamics. PLoS One, 5(9)
Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, Bishop K, Goulder PJ, Walker BD, Brander C, Mullins JI. (2008). Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One, 3(1)
Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, Heath L, Weiner D, Mullins JI. (2007). Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. Journal of virology, 81(16)
Rolland M, Nickle DC, Mullins JI. (2007). HIV-1 group M conserved elements vaccine. PLoS pathogens, 3(11)
Rolland M, Brander C, Nickle DC, Herbeck JT, Gottlieb GS, Campbell MS, Maust BS, Mullins JI. (2007). HIV-1 over time: fitness loss or robustness gain?. Nature reviews. Microbiology, 5(9)
Rolland M, Nickle DC, Deng W, Frahm N, Brander C, Learn GH, Heckerman D, Jojic N, Jojic V, Walker BD, Mullins JI. (2007). Recognition of HIV-1 peptides by host CTL is related to HIV-1 similarity to human proteins. PLoS One, 2(9)
Rolland M, Chauvineau C, Valas S, Mamoun RZ, Perrin G. (2004). Establishment and characterization of a goat synovial membrane cell line susceptible to small ruminant lentivirus infection. Journal of virological methods, 118(2)
Rolland M, Mooney J, Valas S, Perrin G, Mamoun RZ. (2002). Characterisation of an Irish caprine lentivirus strain--SRLV phylogeny revisited. Virus research, 85(1)
If you’d like to update your profile, please email modifications to questions@midasnetwork.us.